TrialPreliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
Trial details
- Registry ID
- NCT01514188
- Phase
- Phase 2
IBRX
ImmunityBio, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
24Trials in this database
19Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourcePilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Trial details
- Registry ID
- NCT01580397
- Phase
- Phase 2
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
Trial details
- Registry ID
- NCT02014844
- Phase
- Phase 2
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
Trial details
- Registry ID
- NCT02029430
- Phase
- Phase 2
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
Trial details
- Registry ID
- NCT02049905
- Phase
- Phase 3
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Trial details
- Registry ID
- NCT02200757
- Phase
- Phase 2
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
Trial details
- Registry ID
- NCT02465957
- Phase
- Phase 2
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Trial details
- Registry ID
- NCT03022825
- Phase
- Phase 2, Phase 3
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Trial details
- Registry ID
- NCT03228667
- Phase
- Phase 2
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
Trial details
- Registry ID
- NCT03520686
- Phase
- Phase 3
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
Trial details
- Registry ID
- NCT03853317
- Phase
- Phase 2
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Trial details
- Registry ID
- NCT04390399
- Phase
- Phase 2
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
Trial details
- Registry ID
- NCT06022224
- Phase
- Phase 2, Phase 3
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Trial details
- Registry ID
- NCT06061809
- Phase
- Phase 2
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
Trial details
- Registry ID
- NCT06710288
- Phase
- Phase 2
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Trial details
- Registry ID
- NCT06745908
- Phase
- Phase 3
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
Trial details
- Registry ID
- NCT06829823
- Phase
- Phase 2
A Study to Assess Anktiva in Patients With Long Covid-19.
Trial details
- Registry ID
- NCT07108036
- Phase
- Phase 2
A Study to Examine Anktiva for the Treatment of COVID-19.
Trial details
- Registry ID
- NCT07123727
- Phase
- Phase 2
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Trial details
- Registry ID
- NCT07125872
- Phase
- Phase 2
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
Trial details
- Registry ID
- NCT07477366
- Phase
- Phase 2
NAI for Sepsis With Persistent Lymphopenia
Trial details
- Registry ID
- NCT07578558
- Phase
- Phase 2
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
Trial details
- Registry ID
- NCT07628062
- Phase
- Phase 2
NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis
Trial details
- Registry ID
- NCT07783789
- Phase
- Phase 2
Latest recorded trial changes
A Study to Examine Anktiva for the Treatment of COVID-19.
NCT07123727 · ImmunityBio, Inc.
Primary completion date changed
− Before
Jul 2026
+ After
Mar 2027
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
NCT06061809 · ImmunityBio, Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
NCT06745908 · ImmunityBio, Inc.
Planned enrollment increased by 47 participants
− Before
460 participants (planned)
+ After
507 participants (planned)
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT03520686 · ImmunityBio, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
1538 participants (planned)
+ After
102 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
31 Oct 2026
+ After
13 Oct 2025
Recruitment status changed
− Before
Active not recruiting
+ After
Terminated
A Study to Assess Anktiva in Patients With Long Covid-19.
NCT07108036 · ImmunityBio, Inc.
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
NCT07125872 · ImmunityBio, Inc.
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667 · ImmunityBio, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Objective Response Rate
Measure: Prolongation of Overall Survival (OS) with NAI Therapy by ALC Response
+ After
Measure: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. Measure: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT04390399 · ImmunityBio, Inc.
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
31 Oct 2025
+ After
13 Oct 2025
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
NCT06061809 · ImmunityBio, Inc.
Recruitment status changed
− Before
Active not recruiting
+ After
Recruiting
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667 · ImmunityBio, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Objective Response Rate
+ After
Measure: Objective Response Rate Measure: Prolongation of Overall Survival (OS) with NAI Therapy by ALC Response
A Study to Assess Anktiva in Patients With Long Covid-19.
NCT07108036 · ImmunityBio, Inc.
Primary completion date changed
− Before
Aug 2026
+ After
Oct 2026
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT03520686 · ImmunityBio, Inc.
Primary completion date changed
− Before
1 Oct 2025
+ After
31 Oct 2026
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
NCT06829823 · ImmunityBio, Inc.
Primary completion date changed
− Before
1 May 2026
+ After
Nov 2026
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT03520686 · ImmunityBio, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Progression Free Survival (PFS)
+ After
Measure: Progression Free Survival (PFS) Measure: Change in absolute lymphocyte count (ALC).